Fierce Biotech October 13, 2023
Relay Therapeutics has decided to extend its race to market. Citing the impact of the Inflation Reduction Act (IRA), the biotech has paused plans to bring lirafugratinib to market in a rare cancer, choosing instead to pursue a larger, tumor-agnostic opportunity.
Boston-based Relay began enrolling patients with FGFR2-fusion cholangiocarcinoma, a rare, aggressive cancer of the bile duct, in a pivotal expansion cohort in December 2021. Enrollment in the cohort is now complete. However, rather than race toward an approval in cholangiocarcinoma while working to validate the drug in larger indications, the biotech has paused preparations to commercialize the asset in the rare cancer.
The shift in strategy follows the generation of data showing lirafugratinib, also known as RLY-4008, may...
Today's Sponsors
Today's Sponsor